

Rapid Evidence Review Addendum

The Oregon Psilocybin Advisory Board (OPAB) [Rapid Evidence Review](#) was published July 30, 2021. Additional relevant references were identified by the 2024 Products and Research Subcommittee of the OPAB. In February 2025, OPAB recommended that the evidence review document be updated to include these additional references. The references have been added as an addendum, but not incorporated into the analysis. The 2025 OPAB members recommend that future OPAB members work to fully update the literature review.

2025 Addendum References

- [Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. *JAMA Psychiatry*. 2022;79\(10\):953-962.](#)
- [Bradshaw AJ, Backman TA, Ramirez-Cruz V, et al. DNA authentication and chemical analysis of psilocybe mushrooms reveal widespread misdeterminations in fungaria and inconsistencies in metabolites. *Applied and Environmental Microbiology*. 2022.](#)
- [Bradshaw AJ, Ramirez-Cruz V, Awan AR, et al. Phylogenomics of the psychoactive mushroom genus *Psilocybe* and evolution of the psilocybin biosynthetic gene cluster. *Proc. Natl. Acad. Sci. U.S.A.* 2024;121\(3\)e2311245121.](#)
- [Cavanna F, Muller S, Alethia de la Fuente L, et al. Microdosing with psilocybin mushrooms: A double-blind placebo-controlled study. *Translational Psychiatry*. 2022; 12:307.](#)
- [De la Salle S, Kettner H, Levesque JT, et al. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. *Scientific Reports*. 2024;14:16524.](#)

- [Farah R, Kerns AF, Murray AC, Holstege CP. Psilocybin exposures reported to U.S. poison centers: National trends over a decade. *Journal of Adolescent Health*. 2024; 74\(5\)1053-1056](#)
- [Hughes ME and Garcia-Romeu A. Ethnoracial inclusion in clinical trials of psychedelics: A systematic review. *Clinical Medicine*. 2024; 74:102711](#)
- [Korthuis PT, Hoffman K, Wilson-Poe AR, et al. Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study. *Journal of Psychopharmacology*. 2024; 38\(8\)761-768.](#)
- [McTaggart AR, McLaughlin S, Slot JC, et al. Domestication through clandestine cultivation constrained genetic diversity in magic mushrooms relative to naturalized populations. *Current Biology*. 2023;33\(23\)5147-5159](#)
- [Miller DR, Jacobs JT, Rockefeller A, et al. Cultivation, chemistry, and genome of *Psilocybe zapotecorum*. *Journal of Psychedelic Studies*. 2024;8\(1\)63-81.](#)
- [Myers M and Slot J. The evolution and ecology of psilocybin in nature. *Fungal Genetics and Biology*. 2023;167:103812.](#)
- [Olson RJ, Bartlett L, Sonneborn A, et al. Decoupling of cortical activity from behavioral state following administration of the classic psychedelic DOI. *Neuropharmacology*. 2023;257\(1\)110030.](#)
- [Polito V and Liknaitzky P. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. *Journal of Psychopharmacology*. 2024\(38\(8\)701-711.](#)
- [Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. *JAMA*. 2023;30\(9\):843-853.](#)
- [Sakai K, Bradley ER, Zamaria JA, et al. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. *Psychopharmacology*. 2023;241:1617-1630.](#)
- [Seibold PS, Dorner S, Fricke J, et al. Genetic regulation of l-tryptophan metabolism in *Psilocybe mexicana* supports psilocybin biosynthesis. *Fungal Biology and Biotechnology*. 2024;11;4.](#)

- [Siegel JS, Subramanian S, Perry D, et al. Psilocybin desynchronizes the human brain. *Nature*. 2024;632;131-138.](#)
- [Simon MW, Olsen HA, Hoyte CO, et al. Clinical effects of psychedelic substances reported to United States poison centers: 2012 to 2022. *Annals of Emergency Medicine*. 2024; 84\(6\)605-618.](#)
- [Strauss D, Ghosh S, Mrray Z, Gryzenhout M. Global species diversity and distribution of the psychedelic fungal genus *Panaeolus*. *Heliyon*. 2023;9\(6\)e16338.](#)
- [Szigeti B, Weiss B, Rosas FE, et. al. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. *Psychological Medicine*. 2024;54\(8\):1717-1724.](#)
- [Van Court RC, Wiseman MS, Meyer KW, et al. Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. *Fungal Biology*. 2023;126\(4\)308-319.](#)
- [Van de Merwe B, Rockefeller A, Killian A, et al. A description of two novel *Psilocybe* species from southern Africa and some notes on African traditional hallucinogenic mushroom use. *Mycologia*. 2024;116\(1\)1-14.](#)
- [Waldbiling A, Baranova M, Neumann S, et al. Exploring *Psilocybe* spp. mycelium and fruiting body chemistry for potential therapeutic compounds. *Frontiers in Fungal Biology*. 2023;4;1295223.](#)

You can get this document in other languages, large print, braille or a format you prefer free of charge. Contact the Oregon Psilocybin Services section at oha.psilocybin@oha.oregon.gov or 1-971-673-0322. We accept all relay calls.

Public Health Division
 Center for Health Protection
 Oregon Psilocybin Services Section
www.oregon.gov/psilocybin
 1-971-673-0322
oha.psilocybin@oha.oregon.gov

